Pulmonary Cell News Volume 13.21 | Aug 15 2024

    0
    96







    2024-08-15 | PULCN 13.21


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 13.21 – 15 August, 2024
    TOP STORY

    Local Receptor-Interacting Protein Kinase 2 Inhibition Mitigates HDM-Induced Asthma

    Researchers evaluated the effectiveness of a pharmacological RIPK2 inhibitor administered locally as a preventive and therapeutic approach using a house dust mite-induced asthma model in wild-type and humanized mice harboring an asthma associated risk allele.
    [European Respiratory Journal]

    Abstract
    PUBLICATIONSListed by the impact factor of the journal
    High-quality equipment, high-quality results. Click to explore.

    Sustained Amphiregulin Expression in Intermediate Alveolar Stem Cells Drives Progressive Fibrosis

    Scientists discovered a close correlation between the distribution pattern of intermediate alveolar stem cells and the progression of fibrotic changes. Amphiregulin (AREG) expression was significantly elevated in intermediate alveolar stem cells of mouse fibrotic lungs and idiopathic pulmonary fibrosis patients.
    [Cell Stem Cell]

    Full ArticleGraphical Abstract

    TNKS1BP1 Mediates AECII Senescence and Radiation Induced Lung Injury through Suppressing EEF2 Degradation

    Researchers reported that radiation up-regulated the TNKS1BP1, causing progressive accumulation of the cellular senescence by up-regulating eukaryotic translation elongation factor-2 (EEF2) in type II alveolar epithelial cells and lung tissue of radiation induced lung injury mice.
    [Respiratory Research]

    Full Article

    Progesterone (P4) Ameliorates Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease (COPD)

    Progesterone (P4) activated the c-MYC/SIRT1 axis, ameliorating cigarette smoke-induced chronic obstructive pulmonary disease and protecting both airway epithelial cells and smooth muscle cells against H2O2-induced oxidative damage.
    [Molecular Medicine]

    Full Article

    Gefitinib (an EGFR Tyrosine Kinase Inhibitor) plus Anlotinib (an Multikinase Inhibitor) for Untreated, EGFR-Mutated, Advanced Non-small Cell Lung Cancer (FL-ALTER): A Multicenter Phase III Trial

    In this Phase III study, 315 patients with treatment-naïve, EGFR-mutated, advanced NSCLC were randomized to receive anlotinib or placebo plus gefitinib once daily on days 1–14 per a three-week cycle.
    [Signal Transduction and Targeted Therapy]

    Full Article

    H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer

    Scientists observed elevated pan lysine lactylation and H3K18la levels in NSCLC tissues, which positively correlated with poor patient prognosis. Interruption of glycolysis by 2-DG and oxamate treatment and silencing of LDHA and LDHB reduced H3K18la levels and circumvented immune evasion of NSCLC cells.
    [Cancer Research]

    Abstract

    Epithelium/imcDC2 Axis Facilitates the Resistance of Neoadjuvant Anti-PD-1 in Human NSCLC

    Multi-omics analyses, including mass cytometry, single-cell RNA-seq, bulk RNA-seq, and polychromatic flow cytometry, were conducted using resected tumor samples in a cohort of NSCLC patients who received neoadjuvant anti-PD-1 therapy.
    [Journal For Immunotherapy of Cancer]

    Abstract

    METTL14-Mediated m6A mRNA Modification of G6PD Promotes Lung Adenocarcinoma

    In lung adenocarcinoma (LUAD) cell lines, both METTL14 and m6A levels were elevated compared to normal human lung epithelial cells. Knockdown of METTL14 markedly reduced LUAD cell proliferation, migration, and invasion.
    [Cell Death Discovery]

    Abstract

    The Splicing Factor SF3B1 Confers Ferroptosis Resistance and Promotes Lung Adenocarcinoma Progression via Upregulation of SLC7A11

    Functional experiments involving SF3B1 knockdown and overexpression demonstrated that SF3B1 facilitated the proliferation, invasion, and migration of lung adenocarcinoma cells.
    [Cancer Gene Therapy]

    Abstract
    Reliably Generate Spheroids with AggreWellâ„¢
    REVIEWS

    Overcoming Resistance in Small-Cell Lung Cancer

    Scientists review the current evidence of the resistance of SCLCs at the cellular level including alteration of key proteins and the possible presence of cancer stem cells.
    [Expert Review of Respiratory Medicine]

    Full Article

    IL-22: A Key Inflammatory Mediator as a Biomarker and Potential Therapeutic Target for Lung Cancer

    The authors discuss the differential expression, regulatory role, and potential clinical significance of IL-22 in lung cancer, while shedding light on innovative approaches for the future.
    [Heliyon]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    With New Grant Funding, Researcher Hopes to Take Down Multiple Causes of Lung Cancer with a Single Strike

    Virginia Commonwealth University Massey Comprehensive Cancer Center’s Dr. Yuesheng Zhang was awarded more than $2.7 million in grant funding to evaluate the effectiveness of a new targeted drug in treating the most common type of lung cancer.
    [Virginia Commonwealth University (EurekAlert)]

    Press Release
    FEATURED EVENT

    Biomolecular Condensates: Mechanisms and Therapeutic Opportunities

    September 6-9, 2024
    Breckenridge, Colorado, United States

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant – Tumor Immunology and Immunotherapy

    Baylor College of Medicine – Houston, Texas, United States

    Senior Oncology Specialist – Lung Cancer

    Amgen, Inc. – Houston, Texas, United States

    Director – Office of Cancer Centers

    National Cancer Institute – Bethesda, Maryland, United States

    Postdoctoral Positions – Biochemistry

    Goethe University Frankfurt am Main – Frankfurt, Germany

    Professor – Science Research

    KU Leuven – Leuven, Belgium

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2